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Androgen deprivation therapy (ADT) is one of the main treatments for prostate cancer. 
Short-term ADT of between 6 months and 3 years is often used in combination with 
radiotherapy to treat localised and locally advanced prostate cancer. Permanent or 
intermittent ADT is used to treat metastatic disease. Hot flushes affect 44-80% of men 
undergoing ADT for prostate cancer, with around 27% saying they are the most distressing 
side effect.1 A recent UK survey found 30.7% of men treated with ADT reported moderate or 
major problems with hot flushes.2 Low testosterone levels are thought to cause dysfunction 
in thermoregulation in the hypothalamus, resulting in peripheral vasodilatation.3 Symptoms 
include a feeling of warmth, flushing of the skin, perspiration, chills, anxiety and 
palpitations. A variety of treatments have been evaluated and there is evidence of efficacy 
for several of them, however they all have additional side effect profiles. The National 
Institute for Health and Care Excellence (NICE) and European Association of Urology 
recommend offering medroxyprogesterone or cyproterone acetate.4-5 NICE has said there is 
currently a lack of evidence to support the use of complementary therapies. Addressing the 
side-effects of cancer treatment is one of the top ten Living with and Beyond Cancer 
research priorities established by the National Cancer Research Institute. However, there is 




To investigate, we designed a survey seeking clinicians’ views on current UK practice in the 
management of hot flushes and whether they would value the opportunity to refer patients 
for acupuncture. The survey included seven questions – six with multiple response options 
and one with free text. Surveys were emailed in November/December 2019 to members of 
the British Uro-oncology Group, whose membership is largely made up of clinical and 
medical oncologists specialising in urology. 
 
Findings 
A total of 64 out of 95 surveys were returned, representing a response rate of 67%. Around 
85% of clinicians reported that at least half their patients experienced hot flushes while on 
ADT. The most common ameliorative interventions recommended were lifestyle changes 
(77%), cyproterone acetate (72%), acupuncture (61%), herbal medicines (59%) and 
medroxyprogesterone (56%) (Figure 1). Satisfaction with all therapies was <50% with the 
proportion saying they were satisfied/very satisfied highest with cyproterone acetate (49%), 
medroxyprogesterone (42%) and acupuncture (37%) (Figure 1). More than 90% of clinicians 
said they would refer patients for acupuncture if it were available on the National Health 
Service (NHS). This view was reflected when clinicians were asked for comments on 
acupuncture and the management of hot flushes more generally. There were no negative 
responses to the use of acupuncture, and many commented on anecdotal evidence of 
efficacy: “Most found it very helpful”; “There is benefit… but doesn't work for all”; “Helps 
about a third of gentlemen”. Many called for more research to inform their practice: 
“Robust trials needed to ensure appropriate use”; “Need to see more evidence”; “I would 
be keen to participate in a trial”.  
 
Conclusion 
The responses to this survey suggest that the management of hot flushes varies greatly, 
with relatively low levels of satisfaction with any of the current treatment options. Clinicians 
were open-minded to complementary treatments and a majority said they would like to 
refer patients for acupuncture and would welcome more research on efficacy for this 
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